GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » ROC (Joel Greenblatt) %

Cabio Biotech (Wuhan) Co (SHSE:688089) ROC (Joel Greenblatt) % : 11.65% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cabio Biotech (Wuhan) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 11.65%.

The historical rank and industry rank for Cabio Biotech (Wuhan) Co's ROC (Joel Greenblatt) % or its related term are showing as below:

SHSE:688089' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.49   Med: 20.59   Max: 50.1
Current: 12.85

During the past 11 years, Cabio Biotech (Wuhan) Co's highest ROC (Joel Greenblatt) % was 50.10%. The lowest was 6.49%. And the median was 20.59%.

SHSE:688089's ROC (Joel Greenblatt) % is ranked better than
86.84% of 1459 companies
in the Biotechnology industry
Industry Median: -330.28 vs SHSE:688089: 12.85

Cabio Biotech (Wuhan) Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -20.00% per year.


Cabio Biotech (Wuhan) Co ROC (Joel Greenblatt) % Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co ROC (Joel Greenblatt) % Chart

Cabio Biotech (Wuhan) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.95 50.10 40.72 14.40 12.69

Cabio Biotech (Wuhan) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.30 11.81 12.86 15.13 11.65

Competitive Comparison of Cabio Biotech (Wuhan) Co's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Cabio Biotech (Wuhan) Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cabio Biotech (Wuhan) Co's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cabio Biotech (Wuhan) Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cabio Biotech (Wuhan) Co's ROC (Joel Greenblatt) % falls into.



Cabio Biotech (Wuhan) Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(214.813 + 112.578 + 61.605) - (97.97 + 0 + 2.351)
=288.675

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(244.207 + 107.449 + 68.18) - (82.592 + 0 + 0.812)
=336.432

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cabio Biotech (Wuhan) Co for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=112.72/( ( (643.275 + max(288.675, 0)) + (666.383 + max(336.432, 0)) )/ 2 )
=112.72/( ( 931.95 + 1002.815 )/ 2 )
=112.72/967.3825
=11.65 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cabio Biotech (Wuhan) Co  (SHSE:688089) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cabio Biotech (Wuhan) Co ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cabio Biotech (Wuhan) Co (SHSE:688089) Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Executives
Shang Yun Core technical personnel
Wang Hua Biao Directors, senior managers
Geng An Feng senior management
Du Bin Director
Yi Hua Rong senior management
Ma Tao senior management
Li Xiang Yu senior management
Wu Yu Jun Supervisors
Xiao Min senior management
Wang Zhi Ming senior management
Lu Shu Huan Core technical personnel
Yi De Wei Director

Cabio Biotech (Wuhan) Co (SHSE:688089) Headlines

No Headlines